Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
about
Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsInvasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitorsFollow-up testing of interferon-gamma release assays are useful in ankylosing spondylitis patients receiving anti-tumor necrosis factor alpha for latent tuberculosis infectionWhat is the future of targeted therapy in rheumatology: biologics or small molecules?Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis.A Drug Delivery System for Administration of Anti-TNF-α Antibody.TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitisAdverse effects of golimumab in the treatment of rheumatologic diseases.IL-6 biology: implications for clinical targeting in rheumatic disease.Amelioration of human osteoarthritis symptoms with topical 'biotherapeutics': a phase I human trial.Cat scratch disease during infliximab therapy: a case report and literature review.Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare.Sinusitis in patients on tumor necrosis factor alpha inhibitors.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects.Safety of tumor necrosis factor inhibitor therapy in patients with a prior malignancy.Survey of rheumatologists on the use of the Philippine Guidelines on the Screening for Tuberculosis prior to use of Biologic Agents.Carcinoma cuniculatum in course of etanercept: blocking autoimmunity but propagation of carcinogenesis?Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-αIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence.Infliximab has no apparent effect in the inner ear hearing function of patients with rheumatoid arthritis and ankylosing spondylitis.Cerebral tuberculoma with pulmonary tuberculosis in a patient with psoriasis treated with adalimumab, an anti-tumor necrosis factor-α agent.FGFR signaling regulates resistance of head and neck cancer stem cells to cisplatin.
P2860
Q26824970-228F4C00-9F59-447E-9D96-D65658699CA2Q29302324-C019416E-1A32-4175-B2D3-E14E5E77E902Q34029954-781E4960-33EF-4F97-91D7-4EB13F0F0293Q35118364-3FFE28EB-7A8F-4B9E-B527-F7ECF44BB5F6Q35842876-9F13E2F5-7371-4236-8440-B75EECBD87B2Q36383550-39B0210B-C1C9-4F30-AC72-6505CB6336B1Q36683809-25C4A8BB-A284-4C05-A4D2-51F6F25D3020Q37236581-378F3EA8-4A55-4E7B-9C76-17910D15E0CBQ38132273-85AB28EB-7D20-4AD8-AD3A-23027DBCA361Q38241232-487B355C-F38B-4C78-8B50-EAE332B7EC0FQ38271768-3CAA8009-B24D-4EEA-A9B5-2D34885BD000Q38303209-A3399830-8D91-4AB5-BD5C-7F9DB00A22B3Q38364465-B0184C79-D5F2-45EB-800A-3187CFEFE8B3Q38538490-8497B9E3-CE0A-4756-9AA0-DA26A6141F72Q39037339-161903FE-3B90-42BA-A640-86F4027A1500Q39264020-106BE217-395B-44E9-B056-580A3A66FC99Q39757212-A7F3B8A2-7315-4CAC-8124-CA348DAB3761Q39811930-C318F768-A811-441E-BDC7-505C95127FE1Q41143403-18BFA1EA-4B1D-4170-AAC2-630B648F379BQ44655782-11E02815-0172-4BC1-B9E5-4136B07C695CQ45058787-D8C18EED-3824-4C0C-97FB-360D46925746Q50155389-7769B2DA-373C-4A31-ABBA-B652037FF56EQ50425514-AA9E4F69-DFEA-4C5D-9744-11AA718A723FQ51574100-40A603E1-3B37-41FD-924A-AACB091C0DC4Q55096590-D4910B43-F787-458A-974A-A838C3341889
P2860
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
@en
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
@nl
type
label
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
@en
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
@nl
prefLabel
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
@en
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
@nl
P2860
P356
P1433
P1476
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
@en
P2093
Archana Jain
P2860
P304
P356
10.2217/IMT.13.10
P577
2013-03-01T00:00:00Z